Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Bland

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive TumorsSophie Archer, Phillip M Brailey, Minjung Song, et al.
Nature Communications|November 16, 2019
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertensionNadine D Arnold, Josephine A Pickworth, Laura E West, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Nature Genetics|July 31, 2023
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress responsePhilip Bland, Harry Saville, Patty T Wai, et al.
Cancer Research|January 29, 2021
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast CancerBarrie Peck, Philip Bland, Ioanna Mavrommati, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive TumorsSophie Archer, Phillip M Brailey, Minjung Song, et al.
Nature Communications|November 16, 2019
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertensionNadine D Arnold, Josephine A Pickworth, Laura E West, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Nature Genetics|July 31, 2023
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress responsePhilip Bland, Harry Saville, Patty T Wai, et al.
Cancer Research|January 29, 2021
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast CancerBarrie Peck, Philip Bland, Ioanna Mavrommati, et al.
Pageof 2